Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a Phase 3 clinical study titled ‘MagnetisMM-32’ to evaluate the effectiveness of elranatamab in patients with relapsed or refractory multiple myeloma, a type of cancer that has returned after previous treatments. The study aims to compare elranatamab monotherapy against other established combination therapies to determine its safety and efficacy.
The study involves two groups: one receiving elranatamab, administered as a subcutaneous injection, and the other receiving a combination of drugs like Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, or Carfilzomib. These treatments are designed to manage multiple myeloma that has not responded to prior therapies.
This interventional study is randomized with a parallel assignment, focusing on treatment as its primary purpose. It is open-label, meaning there is no masking, and participants will be monitored for treatment response and safety.
The study began on February 8, 2024, with an estimated completion date in 2025. The latest update was submitted on July 28, 2025, indicating ongoing recruitment and progress.
This study could significantly impact Pfizer’s market position by potentially introducing a new treatment option for multiple myeloma, influencing stock performance positively. It also places Pfizer in a competitive stance against other pharmaceutical companies in the oncology sector.
The study is currently ongoing, with further details available on the ClinicalTrials portal.